Daré Bioscience, Inc. Appoints Cheryl Blanchard to its Board of Directors to Serve as Class Iii Director
November 12, 2019 at 07:37 am EST
Share
On November 10, 2019, Daré Bioscience, Inc. (Parent), MC Merger Sub, Inc., Microchips Biotech, Inc., and Shareholder Representative Services LLC, solely in its capacity as the representative, agent, and attorney-in-fact of the Effective Time Holders, entered into an Agreement and Plan of Merger (the 'Merger Agreement') pursuant to which, if the transactions contemplated by the Merger Agreement are consummated, Merger Sub will merge with and into Microchips, the separate corporate existence of Merger Sub will cease and Microchips will continue as the surviving corporation and a wholly owned subsidiary of Daré (the “Merger”). The Merger is expected to close on or before November 22, 2019. Under the terms of the Merger Agreement, effective immediately following the closing of the Merger, Cheryl Blanchard, Ph.D., currently the president, chief executive officer and chair of the board of directors of Microchips, will be appointed to Daré’s board of directors to serve as a Class III director. Dr. Blanchard will be joining Daré's board of directors post-closing.
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.